Troglitazone inhibits expression of the phosphoenolpyruvate carboxykinase gene by an insulin-independent mechanism

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1451, Issue 1, 1999, Pages 122-131

  Davies, Gerald F ^a   Khandelwal, Ramji L ^a   Roesler, William J ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Diabetes; Gene expression; Gluconeogenesis; Hepatocyte; Insulin; Peroxisome proliferator activated receptor; Phosphoenolpyruvate carboxykinase; Troglitazone

Indexed keywords

CYCLIC AMP; GLUCOSE 6 PHOSPHATASE; INSULIN; MESSENGER RNA; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); TROGLITAZONE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; ENZYME ACTIVITY; GENE EXPRESSION; GLUCONEOGENESIS; IN VITRO STUDY; LIVER CELL; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; RAT;

ANIMALS; CELLS, CULTURED; CHROMANS; GENE EXPRESSION REGULATION; GLUCONEOGENESIS; GLUCOSE-6-PHOSPHATASE; HYPOGLYCEMIC AGENTS; INSULIN; LIVER; MALE; METFORMIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE (ATP); RATS; RATS, INBRED BB; RATS, SPRAGUE-DAWLEY; RATS, ZUCKER; RNA, MESSENGER; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0032856254     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4889(99)00080-4     Document Type: Article

References (44)

1. Reaven G.M. Role of insulin resistance in the pathophysiology of non-insulin dependent diabetes mellitus. Diabetes Metab. Rev. 9:(Suppl 1):1993;5S-12S.
2. Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, New Engl. J. Med. 329 (1993) 977-986.
3. Rognstad R. Rate-limiting steps in metabolic pathways. J. Biol. Chem. 254:1979;1875-1878.
4. Minassian C., Mithieux G. Differential time-course of liver and kidney glucose-6 phosphatase activity during fasting in rats. Comp. Biochem. Physiol. 109B:1994;99-104.
5. Shrago E., Lardy H.A., Nordlie R.C., Fraser D.O. Metabolic and hormonal control of phosphoenolpyruvate carboxykinase and malic enzyme in rat liver. J. Biol. Chem. 238:1963;3188-3192.
6. Veneziale C.M., Donofrio J.C., Nishimura H. The concentration of P-enolpyruvate carboxykinase protein in murine tissues in diabetes of chemical and genetic origin. J. Biol. Chem. 258:1983;14257-14262.
7. Chang A.Y., Schneider D. Abnormalities in hepatic enzyme activities during development of diabetes in Db mice. Diabetologia. 6:1970;274-278.
8. Nandan S.D., Beale E.G. Regulation of phosphoenolpyruvate carboxykinase mRNA in mouse liver, kidney and fat tissues by fasting, diabetes and insulin. Lab. Anim. Sci. 42:1993;473-477.
9. Valera A., Pujol A., Pelegrin M., Bosch F. Transgenic mice overexpressing phosphoenolpyruvate carboxykinase develop non-insulin-dependent diabetes mellitus. Proc. Natl. Acad. Sci. USA. 91:1994;9151-9154.
10. S.M. Tilghman, F.J. Ballard, R.W. Hanson, in: R.W. Hanson, M.A. Mehlman (Eds.), Gluconeogenesis: Its Regulation in Mammalian Species, Wiley, New York, 1976, pp. 47-87.
11. D.S. Loose, A. Wynshaw-Boris, H.M. Meisner, Y. Hod., R.W. Hanson, in: M.P. Czech (Ed.), Molecular Basis of Insulin Action, Plenum, New York, 1985, pp. 347-368.
12. Saltiel A.R., Olefsky J.M. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 45:1996;1661-1669.
13. Kumar S., Boulton A.J.M., Beck-Nielsen H., Berthezene F., Muggeo M., Persson B., Spinas G.A., Donoghue S., Lettis S., Stewart-Long P. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia. 39:1996;701-709.
14. Ciaraldi T.P., Gilmore A., Olefsky J.M., Goldberg M., Heidenreich K.A. In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism. 39:1990;1056-1062.
15. Fujiwara T., Okuno A., Yoshioka S., Horikoshi H. Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/KsJ-db/db mice. Metabolism. 44:1995;486-490.
16. Teboul L., Gaillard D., Staccini L., Inadera H., Amir E.-Z., Grimaldi P.A. Thiazolidinediones and fatty acids convert myogenic cells into adipose-like cells. J. Biol. Chem. 270:1995;28183-28187.
17. Tafuri S.R. Troglitazone stimulates glucose uptake in 3T3-L1 adipocytes by enhancing the expression of the GLUT1 and GLUT4 glucose transporters. Diabetes. 43:(Suppl. 1):1997;761.
18. Ibrahimi A., Teboul L., Gaillard D D., Amri E.-Z., Ailhaud G., Young P., Cawthorne M.A., Grimaldi P.A. Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol. Pharmacol. 46:1994;1070-1076.
19. 2 is a ligand for the adipocyte determination factor PPARγ Cell. 83:1995;803-812.
20. Cascales C., Mangiapane E.H., Brindley D.N. Oleic acid promotes the activation and translocation of phophatidate phosphohydrolase from the cytosol to particulate fractions of isolated rat hepatocytes. Biochem. J. 219:1984;911-916.
21. Yoo-Warren H., Monahan J.E., Short J., short H., Bruzel A., Wynshaw-Boris A., Meisner H.M., Samols D., Hanson R.W. Isolation and characterization of the gene coding for cytosolic phosphoenolpyruvate carboxykinase (GTP) from the rat. Proc. Natl. Acad. Sci. USA. 80:1983;3656-3660.
22. Lange A.J., Argaud D., El-Maghrabi M.R., Pan W., Maitra S.R., Pilkis S.J. Isolation of a cDNA for the catalytic subunit of rat liver glucose-6-phosphatase: regulation of gene expression in Fao hepatoma cells by insulin, dexamethasone and cAMP. Biochem. Biophys. Res. Commun. 201:1994;302-309.
23. Laborda J. 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Res. 19:1991;3998.
24. Hanson R.W., Patel Y.M. Phosphoenolpyruvate carboxykinase (GTP): the gene and the enzyme. Adv. Enzymol. Relat. Areas Mol. Biol. 69:1994;203-281.
25. Yu B., Pugazhenthi S., Khandelwal R.L. Effects of metformin on glucose and glucagon regulated gluconeogenesis in cultured normal and diabetic hepatocytes. Biochem. Pharmacol. 48:1994;949-954.
26. Saskai K., Cripe T.P., Koch S.R., Andreone T.L., Petersen D.D., Beale E.G., Granner D.K. Multihormonal regulation of phosphoenolpyruvate carboxykinase gene transcription. J. Biol. Chem. 259:1984;15242-15251.
27. Guberski D.L., Butler L., Manzi S.M., Stubbs M., Like A.A. The BBZ/Wor rat: clinical characteristics of the diabetic syndrome. Diabetologia. 36:1993;912-919.
28. Sutherland C., O'Brien R.M., Granner D.K. Phosphatidylinositol 3-inase, but not p70/p85 ribosomal S6 protein kinase, is required for the regulation of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by insulin. J. Biol. Chem. 270:1995;15501-15506.
29. Gabbay R.A., Sutherland C., Gnudi L., Kahn B.B., O'Brien R.M., Granner D.K., Flier J.S. Insulin regulation of phosphoenolpyruvate carboxykinase gene expression does not require activation of the ras/mitogen-activated protein kinase signaling pathway. J. Biol. Chem. 271:1996;1890-1897.
30. Murana K., Inoue Y., Emoto M., Kaku T. Kaneko, CS-045, a new oral antidiabetic agent, stimulates fructose-2,6-bisphosphate production in rat hepatocytes. Eur. J. Pharmacol. 254:1994;257-262.
31. Kurebayashi S., Hirose T., Miyashita Y., Kasayama S., Kishimoto T. Thiazolidinediones downregulate stearoyl-CoA desaturase 1 gene expression in 3T3-L1 adipocytes. Diabetes. 46:1997;2115-2118.
32. De Vos P., Lefebvre A.M., Miller S.G., Guerre-Millo M., Wong K., Saladin R., Hamann L.G., Staels B., Briggs M.R., Auwerx J. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor γ J. Clin. Invest. 98:1996;1004-1009.
33. Marx N., Schonbeck U., Lazar M.A., Libby P., Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ. Res. 83:1998;1097-1103.
34. Fulgencio J.-P., Kohl C., Girard J., Pégorier J.-P. Troglitazone inhibits fatty acid oxidation, and esterification, and gluconeogenesis in isolated hepatocytes from starved rats. Diabetes. 45:1996;1556-1562.
35. Spiegelman B.M. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes. 47:1998;507-514.
36. Tontonoz P., Hu E., Devine J., Beale E.G., Spiegelman B.M. PPARγ2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol. Cell. Biol. 15:1995;351-357.
37. Tafuri S.R. Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes. Endocrinology. 137:1996;4706-4712.
38. Al Rayyes O., Florén C.-H. Troglitazone upregulates LDL receptor activity in HepG2 cells. Diabetes. 47:1998;1193-1198.
39. Masuda K., Okamoto Y., Tsuura Y., Kato S., Miura T., Tsuda K., Horikoshi H., Ishida H., Seino Y. Effects of troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Diabetologia. 38:1995;24-30.
40. Ranganathan S., Kern P.A. Thiazolidinediones inhibit lipoprotein lipase activity in adipocytes. J. Biol. Chem. 273:1998;26117-26122.
41. Young P.W., Buckle D.R., Cantello B.C.C., Chapman H., Clapham J.C., Coyle P.J., Haigh D., Hindley R.M., Holder J.C., Kallender H., Latter A.J., Lawrie K.W.M., Mossakowska D., Murphy G.J., Cox L.R., Smith S.A. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ J. Pharmacol. Exp. Ther. 284:1998;751-759.
42. Raman P., Foster S.E., Stokes M.C., Strenge J.K., Judd R.L. Effect of troglitazone (Rezulin) on fructose 2,6-bisphosphate concentration and glucose metabolism in isolated hepatocytes. Life Sci. 62:1998;89-94.
43. 2+ currents and not endothelial nitric oxide production. Diabetes. 46:1997;659-664.
44. Scheen A.J., Lefèbvre P.J. Oral antidiabetic agents: a guide to selection. Drugs. 55:1998;225-236.